鉬 Molybdenum × 痛風
結論：主流反證據
鉬是黃嘌呤氧化酶（製造尿酸的酵素，正是 allopurinol／febuxostat 所抑制者）的輔因子，補充鉬在機轉上與降尿酸治療完全相反；毒理／職業證據（Kovalskiy 1961 亞美尼亞 10-15 mg/day molybdenosis 類痛風關節病、Seldén 2005 電工個案）顯示過量鉬升高尿酸並誘發痛風樣症狀。
C 🟠 C 薄弱證據 主流反證據 ✨ low — community discussion mostly non-commercial
鉬是黃嘌呤氧化酶（製造尿酸的酵素，正是 allopurinol／febuxostat 所抑制者）的輔因子，補充鉬在機轉上與降尿酸治療完全相反；毒理／職業證據（Kovalskiy 1961 亞美尼亞 10-15 mg/day molybdenosis 類痛風關節病、Seldén 2005 電工個案）顯示過量鉬升高尿酸並誘發痛風樣症狀。
沒有任何 RCT 以鉬治療痛風，亦無任何學會或監管支持，故判 D（反證據／反向訊號）。
須註明劑量依賴性：一般飲食範圍鉬與較低高尿酸風險相關（NHANES OR 0.73、金屬統合分析 OR 0.804，歸因抗氧化），但此為生理範圍觀察性關聯，不構成『鉬治療痛風』之依據。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.44
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 主流反證據
信心度
83%
證據方向一致性高
證據層級
E3
單篇高品質統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.437
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Occupational molybdenum exposure and a gouty electrician (Selden AI et al.; Occup Med, London)
結論：A young male electrician developed hyperuricemia and gouty arthritis associated with occupational molybdenum exposure; symptoms improved during an exposure-free period and relapsed after an exposure reconstruction. Authors note 'Molybdenum is an essential trace element and a component of xanthine oxidase, which catalyses the formation of urate,' but caution the association 'might also be entirely circumstantial.'
前往 PubMed
Endemic molybdenosis (gout-like syndrome) in Ankava, Armenia (Kovalskiy GA et al.)
— 詳細結論請見 PubMed 原文
前往 PubMed
Antioxidative effects of molybdenum and its association with reduced prevalence of hyperuricemia in the adult population (PLoS One)
結論：At normal dietary/environmental exposure ranges, higher urinary molybdenum was significantly associated with LOWER serum uric acid (beta -0.119, 95% CI -0.148 to -0.090) and reduced hyperuricemia risk (OR 0.73, 95% CI 0.64-0.83, p<0.001), attributed to antioxidant effects. Counter-signal to the toxicological harm data and applies only within physiologic intake, not gout-treatment supplementation.
前往 PubMed
A systematic review and meta-analysis of the hyperuricemia risk from certain metals
結論：In pooled biomonitoring data within ordinary exposure ranges, molybdenum was associated with a ~20% LOWER hyperuricemia risk (pooled OR 0.804, 95% CI 0.724-0.975), in contrast to arsenic, cadmium, lead and calcium which raised risk (OR 1.20-1.77). The protective association is at physiologic exposure and does not contradict toxicological evidence that supraphysiologic molybdenum (mg-level) raises urate; it does NOT support molybdenum as a gout treatment.
前往 PubMed
L4a US FDA
支持
The DV for molybdenum is 45 mcg for adults and children age 4 years and older. 來源↗
L4b EU EFSA
支持
Molybdenum contributes to normal sulphur amino acid metabolism. 來源↗
L4c UK NHS
謹慎
Molybdenum is found in many different types of food, such as nuts, canned vegetables, peas, leafy vegetables (like broccoli and spinach), cauliflower and cereals. You should be able to get all the molybdenum you need from your daily diet. 來源↗
L4d TW TFDA / 衛福部
中性
鉬 (Molybdenum) 列於「食品添加物使用範圍及限量暨規格標準」第(七)類營養添加劑，得使用之化合物包括鉬酸鈉 (Sodium molybdate)、鉬酸銨 (Ammonium molybdate)，限用於補充膳食營養之食品 (如錠狀、膠囊狀食品及綜合維生素礦物質產品)，並依使用限量及對象規定添加。 來源↗
L4e WHO
未表態
Molybdenum is considered to be an essential trace element in both animals and humans. Safe and adequate intake levels have been suggested... namely 0.015-0.04 mg/day for infants, 0.025-0.15 mg/day for children aged 1-10 and 0.075-0.25 mg/day for all individuals above the age of 10. The guideline value of 0.07 mg/litre is consistent with the essential daily requirement for molybdenum. 來源↗
L5a NIH Office of Dietary Supplements
支持
Molybdenum deficiency has not been reported, except in people with a genetic mutation that prevents the synthesis of molybdopterin and therefore of sulfite oxidase. In this rare metabolic disorder, known as molybdenum cofactor deficiency, mutations in one of several genes prevent the biosynthesis of molybdopterin. … Molybdenum is not a standard treatment for any disease or disorder. 來源↗
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽
針對「鉬 × 痛風」這個特定組合，PTT（Health／regimen／Doctor-Info）、Dcard、Mobile01、痞客邦、FB 社團幾乎沒有任何鄉民把鉬當作降尿酸／改善痛風保健品的原生實測心得。台灣痛風社群的保健討論幾乎被嘌散、赤晶對策、馭風、訶子（Terminalia chebula）、木犀草素、鵝肌肽（anserine）、薑黃、肉桂、維生素 C、苦瓜胜肽，以及正規降尿酸藥（allopurinol、febuxostat/feburic）所佔據，完全沒有鉬的位置。僅有的『鉬 × 痛風』內容來自百科／毒理衛教頁（維基百科、國衛院國家環境毒物研究中心、A+醫學百科），且方向相反：這些來源指出鉬是黃嘌呤氧化酶（xanthine oxidase，生成尿酸的關鍵酵素）的輔因子，長期過量攝取（>10–15 mg/日，遠超成人 UL 350 µg）反而會升高尿酸並誘發類痛風症狀（亞美尼亞高鉬地區流行病學報告）。因此這是『該保健品在此適應症下台灣社群討論幾近於零、且生化機轉與訴求相悖』的稀疏結果，無在地真實使用經驗可供記錄。
💬社群實感
無共識（針對痛風此適應症，台灣 PTT／Dcard／Mobile01／痞客邦／FB 幾乎無鉬的實測心得；痛風保健討論集中在嘌散、赤晶對策、馭風、訶子、木犀草素、鵝肌肽、薑黃、維生素 C 等，鉬完全不被當作降尿酸選項）
破解迷思 社群最常見的 3 個誤解
✓
事實誤把『鉬是必需微量元素、參與嘌呤代謝』外推為『補鉬有助降尿酸／改善痛風』（生化方向相反：鉬是黃嘌呤氧化酶的輔因子，過量反而促進尿酸生成）
✓
事實誤以為鉬是主流痛風保健成分（台灣痛風社群首選為訶子、木犀草素、鵝肌肽、維生素 C 與正規藥物，鉬幾乎不被討論）
✓
事實忽略『過量鉬（>10–15 mg/日，遠超 UL 350 µg）會升高尿酸並誘發類痛風症狀』的毒理警訊，把微量元素誤當成多多益善的保健品
- 降尿酸藥物治療（allopurinol／febuxostat）
- 急性發作抗發炎藥物（NSAIDs／秋水仙素／類固醇）
- 飲食與生活型態調整
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-gout-INT-molybdenum-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "鉬能改善痛風",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}